Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1350 • ACR Convergence 2024
Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
Tulsi Joishy, Sheau-Chiann Chen, Qiong Wu and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting the joints that is associated with increased cardiovascular risk. Environmental factors play a crucial role…
Abstract Number: 1366 • ACR Convergence 2024
Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³, Hélène Herman-Demars⁴ and René-Marc Flipo⁵, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Nordic Pharma France, Paris, France, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France
Background/Purpose: Methotrexate (MTX) is the first line standard of care for the management of rheumatoid arthritis (RA). In the event of an inadequate response to…
Abstract Number: 1383 • ACR Convergence 2024
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Gong cheng¹, yingni Li¹, Yun Li¹, Feng Sun¹, Hongyan Wang¹, Qinqin li², Zhilun Li³, Ru Li⁴ and Zhanguo Li⁵, ¹Peking University People's Hospital, Beijing, China, ²Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), ³Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, ⁴Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ⁵People’s Hospital Peking University Health Sciences Centre, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
Abstract Number: 1399 • ACR Convergence 2024
A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA
Karin Franck-Larsson¹, Susanne Lindquist², Agneta Wennerholm³, Johan Kolmert⁴, Maria Wanderoy³ and Olle Hernell², ¹Lipum AB, Uppsala, Sweden, ²Lipum AB; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden, ³Lipum AB, Stockholm, Sweden, ⁴Lipum AB; Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Bile Salt-Stimulated Lipase (BSSL) is a lipolytic enzyme secreted by the lactating mammary gland and exocrine pancreas. Elevated plasma levels of BSSL have been…
Abstract Number: 1678 • ACR Convergence 2024
Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study
Eric Jenkins¹, Ingrid Louw², Attila Balog³, Elsa van Duuren⁴, diane Horowitz⁵, Janusz Jaworski⁶, Alan Kivitz⁷, Ilona Kemplerne Ujfalussy⁸, Joe Pirrello¹, Eben Tessari¹, Sheldon Wang¹ and John F Paolini¹, and KPL-404-C211 Investigators, ¹Kiniksa Pharmaceuticals, Lexington, MA, ²Panorama Medical Centre, Cape Town, South Africa, ³Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, ⁴The Sefako Makgatho Health Science University, Pretoria, South Africa, ⁵Feinstein Institute for Medical Research, New York, NY, ⁶Reumatika-Centrum Reumatologii, Warszawa, Poland, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Medical Centre, Hungarian Defense Forces, Dózsa György út 112, Budapest, Hungary
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) with inadequate response or intolerance to current biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have limited options. Abiprubart, a humanized…
Abstract Number: 1785 • ACR Convergence 2024
Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
Martin Stradner¹, Fernanda Monedeiro², Elmar Zuegner², Barbara Prietl³, Monika Oberhuber⁴, Michael Khalil⁵, Christoph Magnes², Hans-Peter Brezinsek¹, Angela Libiseller³ and Thomas Pieber³, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Joanneum Research, Graz, Austria, ³Div. of Endocrinology, Medical University of Graz, Graz, Austria, ⁴CBmed, Graz, Austria, ⁵Dept. of Neurology, Medical University of Graz, Graz, Austria
Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases. Here…
Abstract Number: 1894 • ACR Convergence 2024
Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
Gregory McDermott¹, Mark Hammer², Xiaosong Wang³, Misti Paudel⁴, Sung Hae Chang⁵, Pierre-Antoine Juge⁶, Qianru Zhang⁷, Jessica Lorusso⁸, Amie Samulyov⁸, Kathleen Vanni², Alene Saavedra², Emily Kowalski², Grace Qian³, Katarina Bade², Kevin Mueller², Jeffrey Sparks⁹ and Suzanne Byrne², ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Harard Medical School, Cambridge, ⁸Mass General Brigham, Boston, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Cigarette smoking is a risk factor for both lung cancer and RA. Furthermore, RA is associated with pulmonary abnormalities including interstitial lung disease, bronchiectasis,…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
Abstract Number: 2212 • ACR Convergence 2024
Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort
Rodrigo Garcia Salinas¹, Felicia Almada², Gisel Reyes-Jara², Ronald Perez-Andocillas² and Sebastian Magri³, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: To estimate the frequency of seropositive arthralgia (SA) in a large cohort of patients evaluated for arthralgia in Reuma-check program. To compare the features…
Abstract Number: 2230 • ACR Convergence 2024
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
Maria Garcia-Gonzalez¹, Fuensanta Gomez-Bernal², Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
Abstract Number: 2246 • ACR Convergence 2024
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
Veena Ranganath¹, Holly Wilhalme², Nicolette Morris³, Jenny Brook², Mihaela Taylor¹, Howard Yang¹, Tanaz Kermani⁴, Thanda Aung², Brian Skaggs¹, David Elashoff⁵ and ziva Cooper⁶, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, ⁴University of California Los Angeles, Santa Monica, CA, ⁵UCLA Department of Medicine Statistics Core, Los Angeles, ⁶UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles
Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
Abstract Number: 2284 • ACR Convergence 2024
Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Jesús Loarce³, Nuria Vegas Revenga⁴, María Martín López⁵, Santos Castañeda⁶, Rafael Benito Melero-Gonzalez⁷, Natalia Mena Vázquez⁸, Carmen Carrasco-Cubero⁹, Carolina Díez Morrondo¹⁰, David Castro-Corredor¹¹, Tomás Vázquez Rodríguez¹², Andrea García-Valle¹³, Gema Bonilla¹⁴, Marina Rodriguez¹⁵, Ignacio Brana Abascal¹⁶, Sara María Rojas Herrera¹⁷, Juan Camilo Sarmiento-Monroy¹⁸, Pablo Andújar-Brazal¹⁹, Diego Ferrer²⁰ and Ricardo Blanco-Alonso²¹, and Rest of the Members of the Spanish Collaborative Group of Antifibrotics in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷CHU Ourense, O Carballino, Spain, ⁸IBIMA, Málaga, Andalucia, Spain, ⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁰Complejo Asistencial Universitario de Leon, Leon, ¹¹General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹²Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ¹³Hospital General Río Carrión, Palencia, Spain, ¹⁴H. Universitario La Paz, Madrid, Spain, ¹⁵Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ¹⁷Hospital de Mérida, Badajoz, Spain, ¹⁸Hospital Clínic Barcelona, Barcelona, Spain, ¹⁹Hospital Universitario Doctor Peset, Valencia, Spain, ²⁰Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA), with a prevalence that ranges from 7 to 30% patients with RA,…
Abstract Number: 2590 • ACR Convergence 2024
Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis
Christine Parks¹, Karen Costenbader², Laura Beane Freeman³, Jonathan Hofmann³ and Dale Sandler⁴, ¹National Institute of Environmental Health Sciences, Epidemiology Branch, Rese, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, ⁴Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC
Background/Purpose: Systemic autoimmune rheumatic diseases have been associated with farming exposures, but the role of pesticides has not been well studied. The Agricultural Health Study…
Abstract Number: 2676 • ACR Convergence 2024
Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Jacques MOREL¹, Emmanuelle Dernis², christian roux³, Christophe Richez⁴, OLIVIER BROCQ⁵, Bruno Fautrel⁶, Carine SALLIOT⁷, Olivier Vittecoq⁸, Xavier Mariette⁹, Frédéric LIOTE¹⁰, Slim Lassoued¹¹, Cécile Gaujoux-Viala¹², Arnaud Constantin¹³, MArtin Soubrier¹⁴, Valerie Devauchelle¹⁵, Vincent Goeb¹⁶, Jacques-Eric Gottenberg¹⁷, Hubert Marotte¹⁸, Annouc Rémy Moulard¹, Corinne Merle de Boever¹, Héléna Huguet¹, Odile Launay¹⁹, Florence Galtier¹ and Marie Christine Picot¹, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, ¹CHU and University of Montpellier, Montpellier, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³rheumatology department, university Cote d'Azur, nice, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁶INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁷CHU and University of Orléans, Orléans, France, ⁸CHU and University of Rouen, Rouen, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁰CHU and University of Paris Nord, Paris, France, ¹¹CH of Cahors, Cahors, France, ¹²CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ¹³Hôpitaux de Toulouse, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵UBO, Brest, France, ¹⁶CHu and University of Amiens, Ameins, France, ¹⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁸Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹⁹Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France
Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].